Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Dupilumab targets two specific cytokines — interleukin-4 (IL-4) and interleukin-13 (IL-13) — known to trigger skin issues. It stops them from talking to other cells, which then helps bring ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1 ...

Initiation rates for dupilumab and tezepelumab were similar from 2022 to 2023. Dupilumab and tezepelumab work best with high eosinophil levels. Trends were similar at the study site and patient ...

First line biologic treatment is most often dupilumab, which blocks signaling of the type 2 inflammatory mediators IL-4 and IL-13, but only about 1 out of 3 is optimally treated with dupilumab ...